Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20031909 | 0.95 | MAOB (0.43) | MAOBEGFRHRH3MAOAPPARD | |
| SCHEMBL20031904 | 0.95 | THRA (0.43) | MAOBEGFRTHRATHRB | |
| SCHEMBL20031890 | 0.95 | MAOB (0.38) | MAOBEGFRHRH3MAOAMAPK1 | |
| SCHEMBL20031873 | 0.95 | MAOB (0.38) | MAOBEGFRHRH3PPARDPPARA | |
| SCHEMBL20031650 | 0.95 | MAOB (0.38) | MAOBEGFRHRH3MAOATHRA | |
| SCHEMBL22683257 | 0.94 | MAOB (0.39) | MAOBEGFRHRH3MAOAPPARD | |
| SCHEMBL22703003 | 0.86 | ITGB3 (0.38) | MAOBEGFRPPARDPPARAITGB3 | |
| SCHEMBL22702989 | 0.85 | THRA (0.47) | MAOBEGFRTHRATHRB | |
| SCHEMBL22683269 | 0.84 | BRD4 (0.52) | MAOBEGFR | |
| SCHEMBL30185375 | 0.84 | BRD4 (0.52) | MAOBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578040-B2 | [5]Helicene derivatives as molecular reporters for diagnostic applications and methods of synthesis therefor | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2023-02-14 | — | — | US | disclosed |
| US-11578040-B2 | [5]Helicene derivatives as molecular reporters for diagnostic applications and methods of synthesis therefor | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2023-02-14 | — | — | US | disclosed |
| EP-3518746-B1 | [5]HELICENE DERIVATIVES AS MOLECULAR REPORTERS FOR DIAGNOSTIC APPLICATIONS AND METHODS OF SYNTHESIS THEREFOR | NATIONAL SCIENCE AND TECH DEVELOPMENT AGENCY (TH) | 2020-11-25 | — | — | EP | disclosed |
| EP-3518746-B1 | [5]HELICENE DERIVATIVES AS MOLECULAR REPORTERS FOR DIAGNOSTIC APPLICATIONS AND METHODS OF SYNTHESIS THEREFOR | NATIONAL SCIENCE AND TECH DEVELOPMENT AGENCY (TH) | 2020-11-25 | — | — | EP | disclosed |
| WO-2018063105-A1 | [5]HELICENE DERIVATIVES AS MOLECULAR REPORTERS FOR DIAGNOSTIC APPLICATIONS AND METHODS OF SYNTHESIS THEREFOR | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578040-B2 | [5]Helicene derivatives as molecular reporters for diagnostic applications and methods of synthesis therefor | OR51E2, HDHD5, WEE1 | MAOB 1990/4885EGFR 381/4885HRH3 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.